- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00608439
Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy (CAST)
Centella Asiatica Triterpene Extract for Diabetic Neuropathy -- a Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a clinical trial investigating the effect of an herbal supplement called CAST on diabetic neuropathy. CAST is an herb commonly used in traditional Indian medicine. In this tradition, it is used to increase memory, treat wounds and sores, skin diseases, and neurological conditions such as epilepsy. The herb has had growing popularity in the US; parts are sold as the dietary supplement "gotu kola" and used to improve blood circulation and help heal wounds. Unlike many other herbs, CAST has been extensively researched for many of the above conditions. The compounds found in CAST make it a very promising potential treatment for diabetic neuropathy because of its effect on blood circulation and growth of nerves.
Subjects will receive informed consent. They will then be screened for eligibility before entering the study. A medical history will be taken and subjects will have a neurological exam and vital signs taken. Subjects will have their blood drawn and will also give a urine sample for routine testing. Subjects will have an electrocardiogram (ECG) to check their heart. If a subject is a woman who is at risk of getting pregnant, she will have a urine pregnancy test.
If the subject is eligible for participation in the study, they will return for a total of nine additional study visits over the course of a year. Subjects will be randomly assigned to either receive the active supplement (CAST) or a placebo. A placebo is a pill that tastes, looks, and smells like the study drug but has no real medicine (or supplement) in it. Subjects have a 50% chance of receiving the active supplement. Neither the subject nor the study staff will know who receives the active supplement or the placebo. At visits 2, 7 and 10, subjects will get a comprehensive assessment of their neuropathy symptoms. This will include a Neurological Disability Score assessment, a nerve conduction study and a Quantitative Sensory Test.
Subjects enrolled in the study will begin taking their study pills at the beginning of week 1 of the study. During the first 12 weeks, subjects will be asked to increase their dose by one pill every four weeks. Therefore, they will increase the number of CAST or placebo pills from 60mg twice daily to 60mg four times daily, or the highest dose that does not cause side effects. Dr. Lou will monitor subjects for side effects of the study supplement. At each study visit, blood and urine samples will be taken for safety analysis, including liver and kidney function, and glucose control, and an ECG will be done to monitor heart activity. Subjects will be contacted by the study coordinator via phone call once per week during the first three months of the study. During the remainder of the study, they will be called once each month that they are not scheduled for an appointment. Treatment will conclude after one year.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type II diabetes that is being treated with diet, oral antidiabetic agents and/or insulin
- stable glycemic control over the last 3 months
- evidence of symptomatic symmetrical distal neuropathy
- total symptom score of 4 or more
- stable HbA1c level of less than 8.5 over last three months
Exclusion Criteria:
- Smokers
- Asymmetrical neuropathy of the trunk and proximal lower limbs
- Presence of foot ulcers
- Peripheral vascular disease (non-palpable foot pulses, intermittent claudication)
- Myopathy
- Causes of neuropathy other than diabetes
- Participation in a study of any investigational drug for diabetic neuropathy within 3 months of the study
- Use of any other product containing CA in the last 3 months
- Starting to use antioxidants or Vitamin B within 1 month before the study
- Severe concomitant diseases including neurological disease
- Pregnancy, lactation or being of child-bearing age without birth control
- HBA1c level higher than 8.5
- Use of any experimental drugs in the three months prior to start of the study
- Use of anti-coagulant therapy (heparin or coumarin based drugs)
- A QTc of more than 500 ms at baseline ECG
- Uncontrollable hypertension, defined as diastolic pressure greater than 110, and systolic pressure greater than 160
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo CAST
|
Drug provided to subjects in 60 mg capsules.
Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12.
Subjects remain on highest tolerated dose from week 12 to 52.
Other Names:
|
Active Comparator: Centella asiatica selected triterpenes
Active CAST
|
Placebo provided to subjects in 60 mg color-matched capsules.
Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12.
Subjects remain on highest tolerated "dose" from week 12 to 52.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total Symptom Score
Time Frame: one year
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Nerve Conduction Study
Time Frame: one year
|
one year
|
Neurological Disability Test
Time Frame: one year
|
one year
|
Quantitative Sensory Test
Time Frame: one year
|
one year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R21AT003668 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Neuropathy
-
Tanta UniversityCompletedDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Painful Diabetic Neuropathy | Autonomic Neuropathy | Diabetic Polyneuropathy | Small Fiber NeuropathyEgypt
-
Imperial College LondonActegy Ltd.Not yet recruitingDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Diabetic Polyneuropathy | Diabetic ComplicationUnited Kingdom
-
University of PlymouthNot yet recruitingDiabetic Peripheral Neuropathy | Painful Diabetic Neuropathy
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States
-
AbbVie (prior sponsor, Abbott)CompletedDiabetic Neuropathies | Diabetic Neuropathy, Painful | Diabetic Polyneuropathy | Diabetic Neuralgia | Neuralgia, DiabeticUnited States, Canada, France, Germany, Italy, Mexico, Puerto Rico
-
Power Life Sciences Inc.Not yet recruitingDiabetic Neuropathies | Diabetic Neuropathy Peripheral
-
Khyber Medical University PeshawarActive, not recruitingPeripheral Diabetic NeuropathyPakistan
-
Tanta UniversityActive, not recruiting
-
October 6 UniversityCompletedDiabetic Neuropathy PeripheralEgypt
Clinical Trials on Centella asiatica selected triterpenes (CAST)
-
LG Household & Health Care Ltd.Seoul National UniversityCompleted
-
Oregon Health and Science UniversityActive, not recruiting
-
Oregon Health and Science UniversityNational Center for Complementary and Integrative Health (NCCIH)TerminatedCognitive Impairment | ElderlyUnited States
-
Mustafa Balevi,MDKonya Numune HospitalCompletedTo Prevent Scar Formation for Patients Underwent SurgeryTurkey
-
Oregon Health and Science UniversityAlzheimer's AssociationRecruitingMild Cognitive Impairment | Alzheimer's DiseaseUnited States
-
Sri Hasanamba Dental College and HospitalCompletedGingival DiseasesIndia
-
Indonesia UniversityUnknownDiabetes Mellitus, Type 2 | Xerosis CutisIndonesia
-
Chulabhorn Cancer CenterCompletedBreast Neoplasms | Radiodermatitis | Adverse Effect of Radiation TherapyThailand
-
University of California, DavisCompletedStriae Distensae | Stretch Marks | Cosmetic Appearance of Stretch MarksUnited States
-
University of Bari Aldo MoroUnknown